SynthesisChest2012
Allergen immunotherapy in allergic respiratory diseases: from mechanisms to meta-analyses.
Synthesis in Chest, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Efficacy and safety of sublingual versus subcutaneous immunotherapy in children with allergic rhinitis: a systematic review and meta-analysis.Frontiers in immunology · 2023Pooled it
- What has changed with subcutaneous immunotherapy against house dust mites? Eight-year, single-center real-world data.Asia Pacific allergy · 2025Article
- Allergens in Atopic Dermatitis.Clinical reviews in allergy & immunology · 2025Review
- Article
- Phenotypes and Endotypes in Asthma.Advances in experimental medicine and biology · 2023Article
- Allergic Rhinitis: What Do We Know About Allergen-Specific Immunotherapy?Frontiers in allergy · 2021Review
- Alteration of lung tissues proteins in birch pollen induced asthma mice before and after SCIT.PloS one · 2021Article
- Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma.Allergy · 2020Review
- EAACI Allergen Immunotherapy User's Guide.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2020Review
- Allergy immunotherapy restores airway epithelial barrier dysfunction through suppressing IL-25 -induced endoplasmic reticulum stress in asthma.Scientific reports · 2018Article
- Chinese Guideline on allergen immunotherapy for allergic rhinitis.Journal of thoracic disease · 2017Review
- Vaccine development and new attempts of treatment for ragweed allergy.Therapeutic advances in vaccines · 2015Review
- "The value of pre- and co-seasonal sublingual immunotherapy in pollen-induced allergic rhinoconjunctivitis".Clinical and translational allergy · 2015Article
- The effect of a new communication template on anticipated willingness to initiate or resume allergen immunotherapy: an internet-based patient survey.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2015Article
- Sublingual immunotherapy in allergic rhinitis: efficacy, safety, adherence and guidelines.Clinical and experimental otorhinolaryngology · 2014Review
- Sublingual immunotherapy: World Allergy Organization position paper 2013 update.The World Allergy Organization journal · 2014Article
- Respiratory allergies: a general overview of remedies, delivery systems, and the need to progress.ISRN allergy · 2014Review
- Sublingual delivery of vaccines for the induction of mucosal immunity.Immune network · 2013Article
- Severe asthma: an expanding and mounting clinical challenge.The journal of allergy and clinical immunology. In practice · 2013Review
- Allergen immunotherapy: routes, safety, efficacy, and mode of action.ImmunoTargets and therapy · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Allergen-specific immunotherapy (SIT) involves the repeated administration of allergenic extracts to atopic individuals over a period of 3 to 5 years either subcutaneously (SCIT) or sublingually (SLIT) for the treatment of allergic respiratory diseases, including asthma and allergic rhinitis (AR). In studies, SCIT and SLIT have been shown to improve existing symptoms of asthma and AR and to also have the capability to cause disease-modifying changes of the underlying atopic condition so as to prevent new allergic sensitization as well as arrest progression of AR to asthma. Recent evidence suggests that immunotherapy brings about these effects through actions that use T-regulatory cells and blocking antibodies such as IgG(4) and IgA(2,) which can then result in an "immune deviation" from a T-helper (Th) 2 cell pattern to a Th1 cell pattern. Numerous meta-analyses and studies have been performed to evaluate the existing data among these studies, with the consensus recommendation favoring the use of immunotherapy because of its potential to modify existing diseases. Significant adverse reactions can occur with immunotherapy, including anaphylaxis and, very rarely, death. A primary factor in considering SIT is its potential to provide long-lasting effects that are able to be sustained well after its discontinuation. Given the significant burden these allergic diseases impose on the health-care system, SIT appears to be a cost-effective adjunctive treatment in modifying the existing disease state.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.